Published in Matrix Biol on October 10, 2007
The lens capsule. Exp Eye Res (2008) 1.32
Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res (2014) 1.09
Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials (2009) 1.05
Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol (2013) 0.99
Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model. Biomaterials (2010) 0.96
Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol (2014) 0.94
Perlecan domain IV peptide stimulates salivary gland cell assembly in vitro. Tissue Eng Part A (2009) 0.90
Superficial dermal fibroblasts enhance basement membrane and epidermal barrier formation in tissue-engineered skin: implications for treatment of skin basement membrane disorders. Tissue Eng Part A (2013) 0.84
The nature and biology of basement membranes. Matrix Biol (2016) 0.78
Biomaterials-based strategies for salivary gland tissue regeneration. Biomater Sci (2016) 0.78
Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients. Oncotarget (2016) 0.77
The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect Tissue Res (2015) 0.77
Co-culture of osteocytes and neurons on a unique patterned surface. Biointerphases (2011) 0.77
Two Bioactive Molecular Weight Fractions of a Conditioned Medium Enhance RPE Cell Survival on Age-Related Macular Degeneration and Aged Bruch's Membrane. Transl Vis Sci Technol (2016) 0.75
Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell (1996) 14.75
Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol (1999) 2.94
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem (1996) 2.88
Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood (1995) 2.40
Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol (2005) 2.28
The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem (1991) 2.23
Perlecan is essential for cartilage and cephalic development. Nat Genet (1999) 2.21
Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell Dev Biol (1997) 2.01
Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet (2000) 1.58
Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet (2001) 1.42
Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31. J Biol Chem (1997) 1.41
Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol (1992) 1.37
The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol (2000) 1.37
Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol (1999) 1.33
The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem (1997) 1.25
Perlecan participates in proliferation activation of quiescent Drosophila neuroblasts. Dev Dyn (2002) 1.22
Perlecan--a multifunctional extracellular proteoglycan scaffold. Glycobiology (2007) 1.19
Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem (1999) 1.15
Perlecan proteolysis induces an alpha2beta1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem (2006) 1.11
Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res (2002) 1.09
Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis (2005) 1.05
Novel human endometrial cell line promotes blastocyst development. Fertil Steril (1994) 1.03
Life without perlecan has its problems. J Cell Biol (1999) 1.02
Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng (2005) 1.00
Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol (1999) 0.99
Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr (2005) 0.98
Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem (1997) 0.97
Role of perlecan in skeletal development and diseases. Glycoconj J (2003) 0.96
The role of proteomics in the assessment of premature rupture of fetal membranes. Clin Chim Acta (2005) 0.95
Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J Mol Biol (2001) 0.94
Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin Chim Acta (1996) 0.94
UNC-52/perlecan isoform diversity and function in Caenorhabditis elegans. Biochem Soc Trans (2001) 0.92
Integrins in epithelial cell polarity: using antibodies to analyze adhesive function and morphogenesis. Methods (2003) 0.91
Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC. FASEB J (2004) 0.91
Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun (1999) 0.90
Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J Biol Chem (1995) 0.87
Some effects of the essential fatty acids linoleic acid and alpha-linolenic acid and of their metabolites gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, and of prostaglandins A1 and E1 on the proliferation of human osteogenic sarcoma cells in culture. Prostaglandins Leukot Med (1984) 0.84
Regulation of integrin function by T cell activation: points of convergence and divergence. Immunol Res (1999) 0.81
Perlecan and its immunoglobulin like domain IV are abundant in vitreous and serum of the chick embryo. Matrix Biol (2004) 0.79
MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol (2004) 1.52
Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem (2002) 1.36
MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J (2004) 1.32
Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem (2003) 1.23
Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci (2009) 1.22
Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem (2002) 1.20
Perlecan--a multifunctional extracellular proteoglycan scaffold. Glycobiology (2007) 1.19
Global growth deficiencies in mice lacking the ribosomal protein HIP/RPL29. Dev Dyn (2007) 1.15
Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res (2002) 1.09
Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng (2006) 1.06
Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin Exp Metastasis (2005) 1.05
Progesterone receptor isoforms A and B differentially regulate MUC1 expression in uterine epithelial cells. Mol Endocrinol (2006) 1.03
Repression of HIP/RPL29 expression induces differentiation in colon cancer cells. J Cell Physiol (2006) 1.01
Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. Biochem Biophys Res Commun (2002) 0.99
Heparan sulfate proteoglycans: key players in cartilage biology. Crit Rev Eukaryot Gene Expr (2005) 0.98
Tumor necrosis factor alpha stimulates MUC1 synthesis and ectodomain release in a human uterine epithelial cell line. Endocrinology (2004) 0.98
Differentiation-induced loss of heparan sulfate in human exostosis derived chondrocytes. Differentiation (2005) 0.94
Improved cellular specificity of plasmonic nanobubbles versus nanoparticles in heterogeneous cell systems. PLoS One (2012) 0.94
Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem (2005) 0.92
Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells. Prostate (2011) 0.92
Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis. Birth Defects Res C Embryo Today (2004) 0.92
Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clin Exp Metastasis (2006) 0.91
Mucins and blastocyst attachment. Rev Endocr Metab Disord (2002) 0.91
Perlecan domain IV peptide stimulates salivary gland cell assembly in vitro. Tissue Eng Part A (2009) 0.90
Decidual differentiation of stromal cells promotes Proprotein Convertase 5/6 expression and lefty processing. Endocrinology (2005) 0.89
HIP/RPL29 down-regulation accompanies terminal chondrocyte differentiation. Differentiation (2003) 0.89
The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation. Theranostics (2012) 0.88
MUC1 is a substrate for gamma-secretase. J Cell Biochem (2009) 0.88
Coculture with prostate cancer cells alters endoglin expression and attenuates transforming growth factor-beta signaling in reactive bone marrow stromal cells. Mol Cancer Res (2007) 0.88
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines. J Cell Biochem (2013) 0.85
The MUC1 HMFG1 glycoform is a precursor to the 214D4 glycoform in the human uterine epithelial cell line, HES. Biol Reprod (2007) 0.84
Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression. Mol Endocrinol (2010) 0.84
Heparanase expression and function during early pregnancy in mice. Biol Reprod (2007) 0.84
Expression of human MUC1 during early pregnancy in the human MUC1 transgenic mouse model. Biol Reprod (2009) 0.84
Cytokine and progesterone receptor interplay in the regulation of MUC1 gene expression. Mol Endocrinol (2010) 0.83
Heparan sulfate proteoglycans and their binding proteins in embryo implantation and placentation. Semin Cell Dev Biol (2007) 0.83
MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y. Mol Endocrinol (2007) 0.83
HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses. J Cell Biochem (2008) 0.82
Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Carcinogenesis (2004) 0.82
Compartmental distinctions in uterine Muc-1 expression during early pregnancy in cynomolgous macaque (Macaca fascicularis) and baboon (Papio anubis). Hum Reprod (2005) 0.82
Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab (2011) 0.82
Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro. Connect Tissue Res (2003) 0.81
Ribozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1/2 fibroblasts. Differentiation (2006) 0.80
A rapid and simple nonradioactive method for in vitro testing of ribozyme activity. Antisense Nucleic Acid Drug Dev (2002) 0.80
Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment. J Cell Biochem (2014) 0.80
Perlecan functions in chondrogenesis: insights from in vitro and in vivo models. Cells Tissues Organs (2004) 0.80
Spatiotemporal distribution of heparan sulfate epitopes during murine cartilage growth plate development. Histochem Cell Biol (2006) 0.78
Decidual heparanase activity is increased during pregnancy in the baboon (Papio anubis) and in in vitro decidualization of human stromal cells. Biol Reprod (2007) 0.77
A heparin binding synthetic peptide from human HIP / RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin. J Negat Results Biomed (2003) 0.77